



Doctor Care Anywhere

Innovating Healthcare Together:
Clinician-Led, Product-Driven

FY24 Preliminary Results

27 February 2025



Important Notice and Disclaimer



This presentation is for information purposes only and it is not financial product or investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Doctor Care Anywhere Group PLC, incorporated in England and Wales with company number 08915336 and registered as a foreign company in Australia ARBN 645 163 873 (the "Company"). In preparing this presentation, the Company did not take into account the investment objectives, financial situation or particular needs of any particular reader.

Readers should obtain their own investment, legal and tax advice before taking any action on any information dealt with in the presentation.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation.

No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisors, associated persons or subsidiaries are liable for any direct, indirect or

consequential loss or damage suffered by any person as a result of relying upon any statement in the presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

All amounts are in British pounds (£ or GBP) unless otherwise indicated. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation.

Investors should also be aware that certain financial data included in this presentation including EBITDA and measures described as "pro forma", are "non-IFRS financial information" under ASIC Regulatory Guide 230 (Disclosing non-IFRS financial information). The non-IFRS financial information financial measures do not have a standardised meaning prescribed by Australian International Financial Reporting Standards (AIFRS) and, therefore, may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other financial measures determined in accordance with AIFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial measures included in this presentation.

This presentation may contain forward-looking statements regarding the Company's intent, belief or current expectations with respect to its business and

operations, market conditions, results of operations and financial conditions. Words such as 'will', 'may', 'expect', 'indicative', 'plan', 'intend', 'seek', 'would', 'should', 'risk', 'forecast' and similar expressions indicate forward-looking statements which reflect the Company's current views with respect to future events and are subject to change and involve risks, uncertainties and assumptions that could cause actual outcomes to differ materially from the outcomes anticipated. Accordingly, readers should not place undue reliance on forward-looking statements.

Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change. Subject to applicable law, the Company assumes no obligation to update, review or revise any information contained in this presentation, whether as a result of new information, future events or otherwise. Past performance cannot be relied upon as a guide to future performance.

References to Doctor Care Anywhere in this presentation are to the Doctor Care Anywhere Group including the Company and all subsidiaries, unless stated otherwise

Welcome from CEO



“ Be part of our journey.

We have the right people, technology, and clinical experience to seize the UK healthcare market opportunity.

Laura O’Riordan

CEO, Doctor Care Anywhere

”



Clinician-Led, Product-Driven: Innovating Healthcare Together

The NEW leaders that are driving DCA forward


Chairman





John Stier



Non-Executive Director



David Ravech



Non-Executive Director



Matthew Addison



Non-Executive Director



Dr Sam Shah



Chief Executive Officer



Laura O'Riordan



Chief of Staff



Jamie Aspinall



Chief Customer Officer



Zoe Sullivan



Chief Product & Digital Officer



Andrew Bellingham



Chief Financial Officer



Seema Sangar



Chief Operations Officer



Kristien Bateman



Chief Medical Officer



Vacancy

Who is DCA?


We are a business with the winning formula



Market Opportunity

UK virtual health market value **£681.5m** (CAGR **17.9%** over next 5 years)

7.4m people waiting for NHS treatment and average wait of **two weeks** to see a GP



Best Product

711k consultations per year
3.1m eligible lives
Trustpilot score **4.1** star



Scalable Platform

24/7 service with **100%** of patients seen within 24hrs
99.8% platform availability
Operational excellence:
96% calls answered in **< 60 secs**



Proven Model

Our care model is proven effective, delivering strong outcomes & **operational excellence**
Underlying **cash generative** in H2 2024
Cash reserves to see business through to long term cash generation & profitability



Right Team

A highly skilled clinical & operational workforce (**600+**)
Range of clinician types, primed for **future growth**
Experienced leadership team with backgrounds in **digital health**

Financial Highlights 2024

Continued improvement in all financial metrics



£39.3m

Revenue (A\$77.1m)

+9% BAU on FY23



58%

Underlying gross
profit margin

Up from 46% in FY23



42%

Underlying
contribution margin

Up from 28% in FY23



Underlying EBITDA
loss reduced to

£0.5m (A\$1.0m)

Down from £5.9m in FY23



Underlying cash
generation in
H2 2024

First time in Company's history
metric achieved



£4.4m




(A\$8.6m)

cash in hand at 31 Dec 2024

Sufficient resources through
to profitability







Financial Progress 2022-2024

We are pleased to be on a strong path to profitability, driven by strategic growth and efficiency, with momentum building for long-term investor value



The Market Needs DCA Today

In the UK there is an average wait of 2 weeks to see a GP with 7.4 million people currently waiting for treatment

Market Product Needs	DCA Solutions
 Highly Accessible Services	Rapid Access: 24/7 service, physical & digital, seen in hours not days!
 Differentiated Value Proposition	Personalised Care Pathways: Personalised data drive care outcomes!
 Cost Management	Optimised Cost of Care: Leveraging people and technology
 Digital-First Care Pathways	New Digital Integration: Driving self-management care tools
 Seamless Integration	New Scalable Solutions: Ability for providers to retain their customer journey
 Comprehensive Care	New End to end patient care: Prevention to chronic condition management

Sustainable Growth through Strategic Partners

The result of investing in our growth is shown through the new partners we have onboarded in 2024




Extending our existing portfolio of current partners...



Building Solutions for End-to-End Care




At DCA we are designing and delivering innovative products that seamlessly connect every stage of the healthcare journey



Example - Our Framework in Musculoskeletal Care



In the UK, musculoskeletal conditions accounted for 23.3 million lost workdays in 2022 (est. impact of £2.6b per year), making up around 27% of all work-related absences*.



(*Office for National Statistics)

Thank You...

We're in a good place going into 2025 and are poised for a transformative year.

